Latest Articles
Mali Barbi: Moving Beyond the “One-Size-Fits-All” Era in Endometrial Cancer - Oncodaily
Mali Barbi: Moving Beyond the “One-Size-Fits-All” Era in Endometrial Cancer Oncodaily
Published: Dec. 27, 2025, 7:14 p.m.
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab - OncLive
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab OncLive
Published: Dec. 26, 2025, 1:19 p.m.
Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations - OncLive
Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations OncLive
Published: Dec. 26, 2025, 1:19 p.m.
After comparing endometrial cancer minimally invasive surgery, laparotomy, survival rate and complications... - MSN
After comparing endometrial cancer minimally invasive surgery, laparotomy, survival rate and complications... MSN
Published: Dec. 25, 2025, 7:50 p.m.
Study Explores DPP4’s Role in Ferroptosis and Endometrial Receptivity in PCOS Patients - geneonline.com
Study Explores DPP4’s Role in Ferroptosis and Endometrial Receptivity in PCOS Patients geneonline.com
Published: Dec. 24, 2025, midnight
Targeting DPP4: Ferroptosis and Endometrial Receptivity in PCOS - BIOENGINEER.ORG
Targeting DPP4: Ferroptosis and Endometrial Receptivity in PCOS BIOENGINEER.ORG
Published: Dec. 23, 2025, 7:31 p.m.
Targeting DPP4: Ferroptosis and Endometrial Receptivity in PCOS - Bioengineer.org
Targeting DPP4: Ferroptosis and Endometrial Receptivity in PCOS Bioengineer.org
Published: Dec. 23, 2025, 7:31 p.m.
Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer - Targeted Oncology
Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer Targeted Oncology
Published: Dec. 23, 2025, 2:07 p.m.
First patient dosed in phase 3 trial evaluating ENHERTU in endometrial cancer - Investing.com Nigeria
First patient dosed in phase 3 trial evaluating ENHERTU in endometrial cancer Investing.com Nigeria
Published: Dec. 23, 2025, 2:36 a.m.
Nab-Sirolimus Plus Letrozole Shows Early Activity in Advanced/Recurrent Endometrioid Endometrial Cancer - OncLive
Nab-Sirolimus Plus Letrozole Shows Early Activity in Advanced/Recurrent Endometrioid Endometrial Cancer OncLive
Published: Dec. 22, 2025, 7:02 p.m.
Link copied to clipboard!